Nov. 16, 2023
The Centers for Medicare and Medicaid Services (CMS) recently updated the FAQ for the use of JW and JZ modifiers. Beginning Oct. 1, CMS required the use of JW and JZ modifiers for all claims for drugs from single-use vials or single-use packages payable separately under Medicare Part B. The JW modifier is used to identify any discarded amounts. The JZ modifier is used to attest that there were no discarded amounts. CMS also posted a (non-exhaustive) list of codes subject to the modifier policy.

The American College of Radiology®(ACR®), the Radiology Business Management Association, RadNet, and RayUS met with CMS in September and advocated for the exclusion of imaging contrast agents and radiopharmaceuticals from the JW/JZ reporting requirement. CMS did however indicate the list likely will be updated semi-annually with newly identified codes.

If you have any questions, contact Christina Berry, ACR Team Lead, Economic Policy.

Related ACR News

  • States Still in Session Debate Healthcare Bills

    ACR continues to monitor radiology-specific legislation. With some states still in session, active awareness at the chapter level remains critical.

    Read more
  • Priscilla J. Slanetz, MD, MPH Named RAN Advocate of the Year

    ACR spoke with Dr. Slanetz about her involvement in advocacy and what the Advocate of the Year award means to her.

    Read more
    Dr. Slanetz receiving the RAN Advocate of the Year
  • ACR Leaders Discuss AI with HHS; POTUS AI Plan Released

    Funding for NIH in federal fiscal year (FY) 2026 is uncertain until Congress returns from its August recess.

    Read more